---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-238989"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:52:10.822987+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics appoints Kamal Adawi as CFO, board resignations reduce size from 10 to 8

## Summary
- Kamal Adawi appointed CFO effective Oct 20, 2025; base salary $495k, target bonus 40%.
- Adawi receives 375k stock option and 75k RSUs as inducement equity grants, vesting over 4 years.
- Board members John Mendlein and Neelufar Mozaffarian resigned voluntarily effective Oct 13, 2025.
- Board size decreased from 10 to 8 directors following resignations.
- CFO role focused on supporting registrational path for FT819 in SLE and pipeline progress.

## SEC filing metadata
- accession: 0001193125-25-238989
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/0001193125-25-238989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/fate-20251010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-238989
- JSON: https://secwatch.observer/filing/0001193125-25-238989.json
- Plain text: https://secwatch.observer/filing/0001193125-25-238989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.